LD 1916
pg. 23
Page 22 of 49 PUBLIC Law Chapter 688 Page 24 of 49
Download Chapter Text
LR 2678
Item 1

 
B. Notwithstanding paragraph A, the department may
terminate or suspend the participation of a provider in the
MaineCare program in lieu of recoupment pending final
determination regarding an overpayment as long as 30 days'
notice is given pursuant to federal regulation and state
rule.

 
Sec. C-7. 22 MRSA §42, sub-§7, ¶H, as amended by PL 2003, c. 613, §2,
is further amended to read:

 
H. In an administrative appeal of an informal review
decision under this subsection, the department bears the
burden of proving a violation of law or rule by a
preponderance of the evidence. If the department proves
that existing and available records of goods or services are
defective, the department may impose a fee penalty or
sanction, including total recoupment. Total recoupment for
defective records is warranted only when the provider has
failed to demonstrate by a preponderance of the evidence
that the disputed goods or services were medically
necessary, MaineCare-covered goods or services and were
actually provided to eligible MaineCare members.

 
Sec. C-8. 22 MRSA §2698-A, sub-§§3, 4 and 6, as reallocated by RR 2003,
c. 1, §17 and affected by §18, are amended to read:

 
3. Manner of reporting. By July 1st Beginning in 2006, by
July 1st each year, a manufacturer or labeler of prescription
drugs that directly or indirectly distributes prescription drugs
for dispensation to residents of this State shall file a report
with the department in the form and manner provided by the
department. The report must be accompanied by payment of a fee,
as set by the department in rule, to support the work of the
department under this section.

 
4. Content of annual report by manufacturer or labeler. The
annual report filed under subsection 3 must include the following
information for each calendar year, beginning with calendar year
2005, as it pertains to marketing activities conducted within
this State in a form that provides the value, nature, purpose and
recipient of the expense:

 
A. All expenses associated with advertising, marketing and
direct promotion of prescription drugs through radio,
television, magazines, newspapers, direct mail and telephone
communications as they pertain to residents of this State,
except for expenses associated with advertising purchased
for a regional or national market that includes advertising
within the State;


Page 22 of 49 Top of Page Page 24 of 49
Related Pages
  Search Bill Text Legislative Information
Bill Directory Search
Bill
Status
Session Information
119th Legislature Bills Maine Legislature

Office of Legislative Information
100 State House Station
Augusta, ME 04333
voice: (207) 287-1692
fax: (207) 287-1580
tty: (207) 287-6826
Word Viewer for Windows Disclaimer